Lentiviral Vector Market Report 2026

Lentiviral Vector Market Overview

• Lentiviral Vector market size has reached to $16.48 billion in 2025 • Expected to grow to $30.66 billion in 2030 at a compound annual growth rate (CAGR) of 12.8% • Growth Driver: Lentiviral Vectors Market Driven By Rising Prevalence Of Chronic Diseases • Market Trend: Technological Advancements In Lentiviral Vector Production For Immuno-Oncology Therapies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Lentiviral Vector Market?

A lentiviral vector refers to a type of viral vector derived from lentiviruses, a subgroup of retroviruses known for their ability to integrate genetic material into the DNA of the host cell's genome. These vectors are commonly used in molecular biology and gene therapy applications to deliver genetic material into target cells for various purposes, including gene expression, gene silencing, or genetic modification. The main types of products in the lentiviral vector are kits, reagents and consumables. Lentiviral vector kits encompass a comprehensive set of tools and components required for the generation and manipulation of lentiviral vectors. It can be used for various indications, including cancer, genetic disorders, infectious diseases, veterinary diseases, and others, and it includes various users such as biotechnology companies, pharmaceutical companies, contract research organizations (CROs), and academic and research institutes.

What Is The Lentiviral Vector Market Growth Forecast?

The lentiviral vector market size is expected to see rapid growth in the next few years. It will grow to $30.66 billion in 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to expansion of gene therapy pipelines, adoption of automated vector production systems, collaborations between biotech and pharma companies, emergence of novel lentiviral vector applications, increased demand from emerging markets. Major trends in the forecast period include gene therapy adoption growth, viral vector engineering advancements, regulatory compliance & approval acceleration, increased research funding for genetic disorders, expansion of contract manufacturing capabilities.

Global Lentiviral Vector Market Segmentation

1) By Product Type: Kits, Reagents And Consumables 2) By Indication: Cancer, Genetic Disorder, Infectious Disease, Veterinary Disease, Other Indications 3) By End User: Biotechnology Companies, Pharmaceutical Companies, Contract Research Organization (CRO), Academic And Research Institutes Subsegments: 1) By Kits: Lentiviral Transduction Kits, Lentiviral Packaging Kits, Lentiviral Vector Production Kits 2) By Reagents and Consumables: Lentiviral Packaging Reagents, Lentiviral Vector Concentration Reagents, Transfection Reagents for Lentiviral Vectors

What Is The Driver Of The Lentiviral Vector Market?

The increasing prevalence of chronic diseases is expected to propel the lentiviral vectors market going forward. Chronic diseases refer to long-term medical conditions that typically progress slowly over time and often persist for years or even a lifetime. The prevalence of chronic diseases is increasing due to aging populations, unhealthy lifestyles, urbanization, and environmental factors. Lentiviral vectors offer versatile and efficient tools for developing vaccines and treatment strategies for chronic diseases, addressing unmet medical needs, and improving patient outcomes. For instance, in September 2024, according to the British Heart Foundation, a UK-based cardiovascular research charity, in the UK, approximately 7.6 million people are affected by heart and circulatory diseases, with around 4 million males and 3.6 million females living with these conditions. These diseases are responsible for about 27% of all deaths in the UK, translating to over 170,000 deaths annually, or roughly 480 deaths each day, equating to one death every three minutes. Therefore, the increasing prevalence of chronic diseases is driving the growth of the lentiviral vectors industry.

Key Players In The Global Lentiviral Vector Market

Major companies operating in the lentiviral vector market are Thermo Fisher Scientific Inc., Lonza Group AG, Cytiva, Takara Bio Inc., Promega Corporation, Bio-Rad Laboratories Inc., Merck KGaA, Agilent Technologies Inc., Oxford Biomedica, Sirion-Biotech GmbH, Yposkesi, Applied Biological Materials Inc., OriGene Technologies Inc., Sino Biological Inc., Charles River Laboratories, Vigene Biosciences, VectorBuilder, Cell Biolabs Inc., Addgene, GeneCopoeia Inc.

Global Lentiviral Vector Market Trends and Insights

Major companies operating in the lentiviral vectors market are focusing on developing LV vector production platforms, such as LentiSure, to enhance the efficiency and robustness of producing lentivirus vectors for cell-based immuno-oncology therapies. LentiSure is the LV vector production platform producing lentiviral vectors used in cell-based immuno-oncology therapies. It is designed to enhance efficiency and robustness in generating vectors. For instance, in May 2023, Yposkesi sk pharmteco, a France-based manufacturer of viral vectors, launched LentiSure, an advanced platform designed to enhance the production of lentiviral (LV) vectors, aiming to improve the resilience and efficiency of lentivirus production. This platform addresses the growing demand for robust and economically scalable viral-vector manufacturing technologies in cell and gene therapies. It offers consistent product quality with average titers at cell culture harvest at 10e7 IG/mL bioreactor volume, ensuring higher productivity and success for cell therapy developers.

What Are Latest Mergers And Acquisitions In The Lentiviral Vector Market?

In September 2024, Kyverna Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, signed a license and supply agreement for the LentiVector platform with Oxford Biomedica. This partnership enables Kyverna to leverage Oxford Biomedica’s proprietary lentiviral vector technology for developing gene therapies, particularly for autoimmune diseases. The agreement supports growth and innovation within the lentiviral vector market by providing scalable, reliable vector supply to meet increasing demand. Oxford Biomedica is a UK-based biotechnology company, specializes in providing lentiviral vector platform.

Regional Insights

North America was the largest region in the lentiviral vector market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Lentiviral Vector Market?

The lentiviral vector market consists of sales of 3rd generation lentiviral vectors, Lenti-ORF clones, and lentiviral particles. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Lentiviral Vector Market Report 2026?

The lentiviral vector market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the lentiviral vector industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.